U.S. markets closed

Cyclacel Pharmaceuticals, Inc. (CYCCP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.77+0.02 (+0.30%)
At close: 09:30AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close6.75
Bid6.10 x 1000
Ask7.46 x 1800
Day's Range6.77 - 6.77
52 Week Range5.17 - 11.17
Avg. Volume114
Market Cap12.873M
Beta (5Y Monthly)1.41
PE Ratio (TTM)N/A
EPS (TTM)-2.05
Earnings DateMay 12, 2020
Forward Dividend & Yield0.60 (8.94%)
Ex-Dividend DateOct 14, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CYCCP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cyclacel Pharmaceuticals, Inc.
    Analyst Report: Bristol-Myers Squibb CompanyBristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • GlobeNewswire

    Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors

    BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of Kenneth M. Ferguson, Ph.D., to its Board of Directors. Dr. Ferguson was elected by and will represent the 6% Convertible Exchangeable Preferred stockholders. "We are very pleased to welcome Ken to our Board of Directors,” said Ch

  • Insider Monkey

    10 Popular Penny Stocks on Robinhood

    In this article, we discuss the 10 popular penny stocks on Robinhood. If you want to skip our analysis of these stocks, go directly to the 5 Popular Penny Stocks on Robinhood. According to the letter acquired by CNBC from Citadel Securities’ Institutional Equity Derivatives team, stocks selling below $1 per share recorded an average […]

  • GlobeNewswire

    Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

    - Oral Fadraciclib Demonstrating Strong Safety Profile with Continuous Dosing; anticipate entering Phase 2 POC in 2H 2022 - - First Patients Dosed in Phase 1/2 Study of Oral PLK1 Inhibitor CYC140 for Treatment of Advanced Solid Tumors and Lymphomas - - Publication Confirming Fadraciclib Suppresses MCL1 and Synergistic Activity with Venetoclax in CLL - - Cash Runway through Mid-2023 - - Conference Call Scheduled for May 11, 2022 at 4:30 pm EDT - BERKELEY HEIGHTS, N.J., May 11, 2022 (GLOBE NEWSWIR